VICTORIA, Nov. 20, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF)
announces the realignment of its senior management team as Dr.
James Kuo, Chair of the Board,
assumes the interim position of President of the Company,
Robert Beecroft, founder and
director assumes the role of CEO to further strategically position
the Company together with its European partner, U-Protein Express
B.V. to pursue expansion into the European market and growth
initiatives globally. Thomas D'Orazio will remain as an IPA
director. Dr. Oren Beske will
be pursuing other opportunities.
As interim President, Dr. James
Kuo (MD, MBA) brings considerable senior leadership and
global experience as current Chief Executive Officer of the
Finnish biotechnology company FIT Biotech Ltd. (NASDAQ:
FITBIO). James Kuo is an
experienced biotech industry executive and investor, who brings a
wealth of business and management experience to the Company. He has
held executive positions in private as well as listed biotech
companies in the US. His most recent assignments have been as a CEO
with Biomicro Systems, Inc. and Synthetic Biologics, Inc.
(NYSE:SYN). Prior to that, he was CEO of Discovery
Laboratories, Inc. (NASDAQ:DSCO) after having worked as Associate
Director in corporate licensing and development at Pfizer Inc.
(NYSE:PFE). James Kuo is presently
Chairman of the Board at Athena Bioventures in La Jolla, CA.
Dr. James Kuo stated,
"ImmunoPrecise has assembled an excellent team to work together and
this alignment from within demonstrates the Company's ideals of
strong management as we focus on growth in the coming
quarters. Dr. Kuo continued, "As we continue to build a
strong presence in the human monoclonal antibody segment and grow
our intellectual property through strategic acquisitions and
partnerships, our shareholders can look forward to a steady pace of
activity and regular communications."
Mr. Beecroft was the President, former CEO and founder of
ImmunoPrecise prior to December 2016
and has over 25 years' experience in the development of innovative
and proprietary methods for the production of monoclonal and
polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc
in Microbiology from University of
Victoria and has been involved in over 15 Research Projects
over the course of the last 25 years and been an instructor for
graduate students at the University of
Victoria on the use and production of monoclonal antibodies
for over 13 years. In 2015, Mr. Beecroft was the recipient of
the UVic Distinguished Alumni Award for the Faculty of Science, in
recognition for being the Founder of ImmunoPrecise Antibodies
Ltd.
About ImmunoPrecise Antibodies Ltd.
The Company provides custom antibody development and production
services and protein expression to support research and development
programs at leading pharmaceutical and biotechnology companies, as
well as academic research laboratories. Antibodies are
naturally occurring proteins capable of binding to specific target
molecules, or antigens. They have been used very widely in research
assays, diagnostics, purification, biologics and therapeutics.
The Company operates from state of the art laboratory facilities
located at the Vancouver Island Technology Park in Victoria, British Columbia which house its
tissue culture and molecular facilities as well as an animal care
unit, and is a member of the Canadian Council for Animal Care and
in association with U-Protein Express B.V. its subsidiary
laboratory operation in Life Science Incubator, Utrecht Science
Park, Utrecht, the Netherlands.
.
The services offered to customers include the development of
mouse and rat monoclonal and recombinant rabbit monoclonal
antibodies against a wide spectrum of antigens, as well as
polyclonal antibodies, immunologically based assays, and solutions
to challenges faced by clients in antibody related research and
development. In addition, cryopreservation services are
provided for the storage of valuable biological materials including
hybridoma clones, plasmid constructs, and cell lines. The
antibodies produced by the Company target a wide variety of
environmental, diagnostic and research applications.
The Company employs a highly experienced group of R&D
scientists. Over the last 25 years, investments in innovative
and proprietary technologies and methods have vastly improved the
speed and efficiency of monoclonal and polyclonal antibody
production.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. ImmunoPrecise uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's
actual results to differ materially from those expressed or implied
by the forward-looking statements contained in this news release.
Such factors include, among other things: risks and uncertainties
described in the Company's Filing Statement dated December 13, 2016 which can be accessed at
www.sedar.com. The "forward-looking statements" contained herein
speak only as of the date of this press release and, unless
required by applicable law, the Company undertakes no obligation to
publicly update or revise such information, whether as a result of
new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.